I was wondering how can CCL make a money with winter coming, people are conscious of calories and sugar . Interestingly I found Bell Potter and another Sydney broker have recommended CCL as a buy whereas the below article says CCL is a buy.
So confusing and my gut feeling says, CCL is a sell regardless what charts appearing.
Your thoughts please
Regards
BROKER SAYS :
coca-Cola Amatil Ltd (CCL) $8.66.
Up 2.97% (please see chart attached or below).
On the 1:2 Trend Line (= 1 unit of Price to 2 units of Time)
- Double Bottom Reversal Pattern
- Peter Steidelmayer b-Formation (= Buy the Lower 1/8)
Trade Idea:
Buy the June 1 Cent Call
Mental Sell Stop Limit Below (at $8.00 or Above)
For Example – General Advice Only:
isk if sold at $8.00: ($8.66 – $8.00) x 2,500 =
$1,650. More if sold below $8.00 (plus transaction costs).
================
Sell - broker 2
Coca-Cola Amatil
(CCL.AX)
Raising debt, withdrawing dividend guidance as COVID-19 impacts
18 April 2020 | 12:12PM AEST
CCL provided an update to market, post the end of peak summer trading (marked by Easter) and leading into Ramadan trading peak in Indonesia. Group volumes increased low single digits in 1Q20 but fell 30% in the first two weeks of April. Australian volumes declined 15% in April with On-The-Go (OTG) down 50%. EBIT declined mid teens percentages in 1Q20. CCL will provide another COVID-19 update at its AGM on May 26.
The outlook was modestly more adverse than anticipated in our note,
Exposed to lock downs from April 6. Loss of high margin OTG sales will be a significant earnings headwind in 2020, though partly offset by forecast cost reductions of A$140mn (mostly temporary).
The telling feature of this update is the effort CCL is going to in order to bulk up its defences through increased debt funding (A$200mn raised and another A$150mn anticipated in this half), reduced capex guidance (from A$300mn to A$200mn) and withdrawal of its dividend payout ratio guidance (previously "above 80%"). CCL has a strong balance sheet with BBB+ credit rating (S&P), and we forecast this to remain the case over 2020, before improving in 2021. In our view, the preemptive fundraising highlights how unpredictable conditions are for CCL currently.
NPAT forecasts have been revised -2% in FY20 but FY21 forecasts are unchanged. GSe was 15% below consensus in FY20 into this update, so we expect a greater earnings impact to consensus forecasts. EPS of A$0.443 implies a 2020 PE of 19.5x. Our 12-month target price is at A$8.90 implying upside of +3.1%. We are Sell-rated on CCL.
Trading update shows material step down
CCL reported low single digit volume and revenue growth, EBIT was down by a mid-teens percentage for the quarter due to bushfires in Australia, additional marketing expenditure in Indonesia and impact of social distancing restrictions across various regions, with positive impacts in supermarkets unable to offset the detrimental trends in On-The-Go channels.
- Australia volumes were down 1% in 1Q20 but with mid-teens percentage impact on EBIT. Volumes were however down -15% in the first two weeks of April, mainly led by decline in OTG by -50% (GSe base case impact -55%). Alcohol volumes in the region were also down 20% due to stronger on premise declines.
- New Zealand and Fiji revenue was up low single digits and EBIT up low teen percentage in 1Q20. The first two weeks of 2Q20 however registered a 25% decline in volumes.
- Indonesia and PNG volumes were up mid single digits in 1Q20, but resulting in an EBIT loss due to increased wage and marketing costs. Trading in the first 2 weeks of April was down c.50% in Indonesia and -40% in PNG.
- COVID-19 response: Management has guided on FY20 capex target being reduced to A$200mn (vs. A$300mn earlier). Additionally, the group is also targeting cost savings of A$140mn, before the benefit of government support.
- Balance Sheet: The group has successfully placed 10-year notes of A$200mn on 6th April 2020 and is looking to raise another A$150mn. As at 31 March 2020, the group also had c.A$1.8bn of debt facilities (A$2.6bn of committed facilities) and A$920mn of cash.
- Dividend payout ratio guidance has been withdrawn.
Earning changes
We revise our group EBIT estimates for FY20 by -3.2% and FY21 by -0.2%. These changes are largely driven by:
- Indonesia and PNG: Sales volumes in this region has been reported to be down -50% and -40% respectively in Indonesia and PNG during the 1st two weeks of April. These declines are well ahead of our earlier expectations and we expect this to remain significant through the key Ramadan trading period. Resultantly, we revise our FY20 sales estimates by -18.5% and EBIT estimates by -35.4%, the higher impact of operating leverage being partially offset by the cost savings initiatives.
- Australia and NZ and Fiji: We revise the Australia estimates by +4.4% and New Zealand and Fiji by +0.8% for FY20 accounting for the larger-than-expected cost savings initiatives announced. However, we expect this to be largely temporary and do not forecast these cost savings to be continued in FY21 and beyond.
Exhibit 1 : CCL: Summary of earnings revisions
Source: Company data, Goldman Sachs Global Investment Research
Overall, we revise our NPAT forecasts by -2% in FY20 but maintain FY21 forecasts unchanged.
We also revise FY20 capital expenditure forecasts to be in line with management guidance of A$200mn due to reduced spending on discretionary projects.
Balance Sheet: Despite the significant earnings uncertainties seen for CCL in the near-term, we remain comfortable regarding the group's balance sheet position. The group has debt maturities worth A$305mn coming up for repayment in FY20 and A$310mn in FY21.
We expect dividend to be reduced to A??37 in FY20 vs. A??47 in FY19, with payout at c. 84% (despite withdrawn payout guidance of "more than 80%"). Post dividend payment, we forecast Free cashflow to be positive at c. A$74mn (inclusive of A$60mn reduction in tax due to utilisation of deferred tax assets). Lease adjusted net debt to EBITDA is forecast to increase to c. 2.7x (adjusted for the cash deposit in Indonesia and PNG) in FY20, below S&P's 3x threshold for CCL's BBB+ credit rating.
Exhibit 2 : Free cash flow post dividend obligations is expected to remain skinny in FY20
Source: Company data, Goldman Sachs Global Investment Research
Exhibit 3 : CCL's leverage for FY20 is expected to increase to 2.7x on a lease adjusted basis, but reduce beyond that
Source: Company data, Goldman Sachs Global Investment Research
Valuation and Risks
Our fundamental valuation for CCL (85% weighting) remains based on a 50/50 weighted split of EV/EBIT-based SOTP and DCF valuation. Our FY20 EV/EBIT-based SOTP valuation is at A$7.40 (vs. A$7.50 earlier). Our DCF implies a net present value of A$10.30 (vs. A$10.10 earlier). In addition to the fundamental valuation, we include an M&A value of A$9.30 (vs. A$9.50 earlier) (15% weighting) which is based on the historic peak P/E multiple for the stock (21x). Our 12-month target price remains at A$8.90 implying upside of +3.1%. We are Sell-rated on CCL.
Exhibit 4 : Our Target Price on CCL remains unchanged at A$8.90
Source: Goldman Sachs Global Investment Research
Key upside risks are: Less competition in the grocery channel, better CSD category growth, larger than expected cost savings, and successful implementation of the 'Beverages for Life' strategy.
Andrew McLennan
+61 2 9320-1488
andrew.j.mclennan@gs.com
Goldman Sachs Australia Pty Ltd
Darshana Nair Syama
+61 2 9320-1395
darshana.nairsyama@gs.com
Goldman Sachs Australia Pty Ltd
Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the
Disclosure Appendix, or go to
www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.